Don't Miss


Idiopathic Pulmonary Fibrosis (IPF): KOL Insight. offers business critical insights from 12 leading US and European Key Opinion Leaders on what is influencing clinician’s prescribing decisions and which pipeline products are changing the future treatment paradigm for IPF. Learn more.

US seeks up to $3.35 billion from Novartis over alleged kickbacks to boost Exjade, Myfortic sales